📊 CRSP Key Takeaways
Is CRISPR Therapeutics AG (CRSP) a Good Investment?
CRISPR Therapeutics faces critical operational deterioration with revenue collapsing 90.6% YoY to $1.5M while sustaining -$130.2M operating losses and burning -$109.4M in free cash flow annually. Despite a fortress balance sheet providing estimated 4-5 year runway, the company shows no profitability trajectory and is rapidly consuming shareholder capital with negative margins exceeding -8400%.
CRISPR Therapeutics' fundamentals show a classic development-stage biotech profile: minimal and highly volatile revenue, very large operating losses, and deeply negative free cash flow. The main offset is an exceptionally strong balance sheet, with substantial cash, no meaningful long-term debt, and very high liquidity, which gives the company time to fund R&D and absorb commercialization delays. Fundamental upside depends less on current earnings quality and more on whether revenue becomes durable while cash burn narrows.
Why Buy CRISPR Therapeutics AG Stock? CRSP Key Strengths
- Exceptional liquidity position with 17.96x current ratio and $423.3M cash providing multi-year operational runway
- Conservative leverage at 0.32x debt-to-equity with manageable $585.5M long-term debt
- Substantial $2.7B asset base and $1.8B stockholders' equity provides financial flexibility
- Very strong liquidity profile, with cash of $347.56M and current and quick ratios of 13.32x
- Debt-free balance sheet and $1.92B equity base provide financial flexibility
- Large asset base relative to liabilities reduces near-term solvency pressure
CRSP Stock Risks: CRISPR Therapeutics AG Investment Risks
- Revenue collapse of 90.6% YoY to $1.5M signals severe loss of revenue stream or major contract termination
- Negative free cash flow of -$109.4M annually with no visible path to cash flow breakeven
- Operating losses of -$130.2M require successful clinical breakthroughs or external financing within finite cash runway
- Revenue fell 90.6% year over year, indicating weak revenue durability and poor growth quality
- Operating loss of $664.57M and net loss of $581.60M reflect an unsustainable profitability profile
- Negative operating cash flow of $345.01M shows continued heavy cash consumption that could pressure future funding needs
Key Metrics to Watch
- Quarterly revenue stabilization and new partnership/contract announcements
- Operating cash flow recovery trajectory and monthly burn rate trends
- Clinical trial advancement milestones and regulatory approval progress
- Cash balance depletion rate and need for equity or debt financing
- Quarterly revenue consistency and commercialization-related revenue growth
- Operating cash burn relative to cash and equivalents
CRISPR Therapeutics AG (CRSP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 17.96x current ratio provides a solid financial cushion.
CRSP Profit Margin, ROE & Profitability Analysis
CRSP vs Healthcare Sector: How CRISPR Therapeutics AG Compares
How CRISPR Therapeutics AG compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CRISPR Therapeutics AG Stock Overvalued? CRSP Valuation Analysis 2026
Based on fundamental analysis, CRISPR Therapeutics AG has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CRISPR Therapeutics AG Balance Sheet: CRSP Debt, Cash & Liquidity
CRSP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CRISPR Therapeutics AG's revenue has declined by 59% over the 5-year period, indicating business contraction. The most recent EPS of $-1.94 indicates the company is currently unprofitable.
CRSP Revenue Growth, EPS Growth & YoY Performance
CRSP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $865.0K | -$122.9M | $-1.28 |
| Q3 2025 | $602.0K | -$85.9M | $-1.01 |
| Q2 2025 | $517.0K | -$116.6M | $-1.49 |
| Q1 2025 | $504.0K | -$116.6M | $-1.43 |
| Q3 2024 | N/A | -$53.1M | $-1.01 |
| Q2 2024 | $517.0K | -$53.1M | $-0.98 |
| Q1 2024 | $504.0K | -$53.1M | $-0.67 |
| Q3 2023 | N/A | -$53.1M | $-1.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CRISPR Therapeutics AG Dividends, Buybacks & Capital Allocation
CRSP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CRISPR Therapeutics AG (CIK: 0001674416)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRSP
What is the AI rating for CRSP?
CRISPR Therapeutics AG (CRSP) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRSP's key strengths?
Claude: Exceptional liquidity position with 17.96x current ratio and $423.3M cash providing multi-year operational runway. Conservative leverage at 0.32x debt-to-equity with manageable $585.5M long-term debt. ChatGPT: Very strong liquidity profile, with cash of $347.56M and current and quick ratios of 13.32x. Debt-free balance sheet and $1.92B equity base provide financial flexibility.
What are the risks of investing in CRSP?
Claude: Revenue collapse of 90.6% YoY to $1.5M signals severe loss of revenue stream or major contract termination. Negative free cash flow of -$109.4M annually with no visible path to cash flow breakeven. ChatGPT: Revenue fell 90.6% year over year, indicating weak revenue durability and poor growth quality. Operating loss of $664.57M and net loss of $581.60M reflect an unsustainable profitability profile.
What is CRSP's revenue and growth?
CRISPR Therapeutics AG reported revenue of $1.5M.
Does CRSP pay dividends?
CRISPR Therapeutics AG does not currently pay dividends.
Where can I find CRSP SEC filings?
Official SEC filings for CRISPR Therapeutics AG (CIK: 0001674416) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRSP's EPS?
CRISPR Therapeutics AG has a diluted EPS of $-1.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CRSP a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, CRISPR Therapeutics AG has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CRSP stock overvalued or undervalued?
Valuation metrics for CRSP: ROE of -6.8% (sector avg: 15%), net margin of -8,431.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CRSP stock in 2026?
Our dual AI analysis gives CRISPR Therapeutics AG a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRSP's free cash flow?
CRISPR Therapeutics AG's operating cash flow is $-108.9M, with capital expenditures of $504.0K. FCF margin is -7,503.5%.
How does CRSP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8,431.5% (avg: 12%), ROE -6.8% (avg: 15%), current ratio 17.96 (avg: 2).